Intestinal Organoids

Crohn Disease Clinical Trial

— BIOÏDES  

Official title:

Intestinal Organoids

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05294107
• Other study ID #: 35RC21_8862_BIOÏDES
• Status: Recruiting
• Phase: N/A
• Start date: September 6, 2022
• Est. completion date: September 2024

Study information

• Verified date: November 2023
• Source: Rennes University Hospital
• Contact: Guillaume BOUGUEN, Professor
• Phone: 2 99 28 99 72
• Email: guillaume.bouguen[@]chu-rennes.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Over the last decade, the use of mini-organ or organoids has been increasingly developed in fundamental research. Indeed, digestive organoids represent an essential advance compared to classical culture systems (epithelial cell lines, immortalized cells) since they preserve in culture the functional complexity present in vivo (architecture, different cell types). They also have the advantage of being able to be propagated indefinitely (unlike explants), minimizing the use of animal models and reducing the amount of tissue required. Finally, their growth and development depends on the origin of the sample (the organoid will develop differently if the cell source comes from a patient suffering from an inflammatory bowel disease, for example), thus generating models of human pathologies to better determine their physiopathology. The use of organoids in biomedical research has proven to be an indispensable tool for the understanding of cellular and molecular mechanisms involved in epithelial renewal and the screening of molecules and ingredients for applications in the health and agri-food sectors.

Description:

The project aims to generate a biocollection of 3D intestinal models from digestive biopsies with associated health data and to characterize them before using them for the screening of potential therapeutic molecules.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: September 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Subjects aged 18 to 75 years

• Subject undergoing endoscopy as part of the standard of care with the need to take digestive biopsy samples

• Subject having signed a free and informed consent in writing

Exclusion Criteria:

• Subjects under legal protection (safeguard of justice, curatorship or guardianship) or deprived of liberty.

• Anticoagulant treatment and anti-platelet treatment (except for aspirin 75 mg)

Related Conditions & MeSH terms

• Colitis, Ulcerative
• Crohn Disease
• Digestive System Diseases
• Gastrointestinal Diseases
• Inflammatory Bowel Disease, Ulcerative Colitis Type
• Inflammatory Bowel Diseases
• Intestinal Diseases

Intervention

Procedure:
• additional biopsies
After Verification of eligibility criteria, patient information and consent, digestive biopsies performed for the study are in addition to those performed for the patient's follow-up: 6 biopsies are taken on average in clinical routine 4 additional biopsies are necessary to obtain a sufficient number of amplifiable stem cells The samples will be sent within one hour to the Biological Resource Center of the University Hospital of Rennes at room temperature in a tube containing isotonic saline. (CRB). Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing.

Locations

Country	Name	City	State
France	CHU de RENNES-Service des Maladies de l'Appareil Digestif	Rennes

Sponsors (1)

Lead Sponsor	Collaborator
Rennes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of isolated intestinal crypts per biopsies	Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing.	Day 0
Secondary	Number of differentiated organoids		Day 0
Secondary	Fold change of MUC2 expression		Day 0
Secondary	Fold change of LGR5 expression		Day 0
Secondary	KI67 expression		Day 0